This Article Full Text Full Text (PDF) All Versions of this Article: 90/4/2264    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garin, M.-C. B. Articles by James, R. W. Search for Related Content PubMed PubMed Citation Articles by Garin, M.-C. B. Articles by James, R. W. Related Collections Metabolism Lipid

Small, Dense Lipoprotein Particles and Reduced Paraoxonase-1 in Patients with the Metabolic Syndrome

Clinical Diabetes Unit (M.-C.B.G., B.K., R.W.J.), Department of Endocrinology, Diabetes, and Nutrition, and Department of Clinical Epidemiology (A.M.), University Hospital, 1211 Geneva 4, Switzerland

Address all correspondence and requests for reprints to: Dr. Richard W. James, Clinical Diabetes Unit, Department of Endocrinology, Diabetes, and Nutrition, University Hospital, 1211 Geneva 4, Switzerland. E-mail: richard.james{at}hcuge.ch.

The presence of the metabolic syndrome (World Health Organization definition) and its association with lipoprotein abnormalities suggestive of greater susceptibility to oxidative stress have been analyzed in patients with angiographically defined coronary artery disease. The odds ratio for the presence of the metabolic syndrome was significantly higher in coronary artery disease-positive patients (P < 0.001). The metabolic syndrome was also associated with more severe coronary disease (P < 0.01). Patients with the metabolic syndrome had significantly decreased low-density lipoprotein-cholesterol/apolipoprotein B and high-density lipoprotein-cholesterol/apolipoprotein AI ratios, indicative of the presence of small, dense lipoprotein particles. The syndrome was also associated with reduced concentrations and activities of the antioxidant enzyme, paraoxonase-1. The metabolic syndrome is characterized by smaller, denser lipoprotein particles that increase their susceptibility to oxidative modifications and diminished serum paraoxonase-1, which is a major determinant of the antioxidant capacity of high-density lipoproteins. These may be contributory factors to the increased presence and severity of coronary disease in such patients.

This article has been cited by other articles:

				C. Wolfrum, J. J. Howell, E. Ndungo, and M. Stoffel Foxa2 Activity Increases Plasma High Density Lipoprotein Levels by Regulating Apolipoprotein M J. Biol. Chem., June 13, 2008; 283(24): 16940 - 16949. [Abstract] [Full Text] [PDF]

				A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]

				B. Mackness, R. Quarck, W. Verreth, M. Mackness, and P. Holvoet Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1545 - 1550. [Abstract] [Full Text] [PDF]